MGTX
NASDAQ · Biotechnology
Meiragtx Holdings Plc
$7.62
+0.21 (+2.83%)
Financial Highlights (FY 2026)
Revenue
39.16M
Net Income
-173,924,544
Gross Margin
28.5%
Profit Margin
-444.1%
Rev Growth
-4.1%
D/E Ratio
1.08
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 28.5% | 28.5% | 65.8% | 65.8% |
| Operating Margin | -493.4% | -444.1% | -9.9% | -11.8% |
| Profit Margin | -444.1% | -421.9% | -10.4% | -12.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 39.16M | 40.82M | 298.22M | 353.14M |
| Gross Profit | 11.16M | 11.64M | 196.30M | 232.45M |
| Operating Income | -193,236,847 | -181,291,735 | -29,566,882 | -41,721,150 |
| Net Income | -173,924,544 | -163,173,240 | -30,982,952 | -42,442,765 |
| Gross Margin | 28.5% | 28.5% | 65.8% | 65.8% |
| Operating Margin | -493.4% | -444.1% | -9.9% | -11.8% |
| Profit Margin | -444.1% | -421.9% | -10.4% | -12.0% |
| Rev Growth | -4.1% | -4.1% | -0.7% | -1.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 153.56M | 153.56M | 274.26M | 257.56M |
| Total Equity | 142.25M | 142.25M | 356.05M | 341.85M |
| D/E Ratio | 1.08 | 1.08 | 0.77 | 0.75 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -159,676,650 | -158,128,653 | -39,492,333 | -49,405,433 |
| Free Cash Flow | — | — | -35,501,473 | -31,424,329 |